Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 929-934

  Zhao, L ^a,b,c   Grob, S ^b   Avery, R ^d   Kimura, A ^e   Pieramici, D ^d   Lee, J ^b   Rabena, M ^d   Ortiz, S ^b   Quach, J ^b   Cao, G ^c   Luo, H ^b,c   Zhang, M ^c   Pei, M ^b   Song, Y ^b   Tornambe, P ^f   Goldbaum, M ^b   Ferreyra, H ^b   Kozak, I ^b   Zhang, K ^a,b,c  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SICHUAN UNIVERSITY   (China)

^d California Retina Consultants and Research Foundation   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f San Diego Retina Research Foundation   (United States)

Author keywords

Anti VEGF therapy; Choroidal neovascularization; Genetics; Macular degeneration; VEGFA

Indexed keywords

BEVACIZUMAB; GENOMIC DNA; RANIBIZUMAB;

AGED; ALLELE; ARTICLE; BODY MASS; COHORT ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENCE ANGIOGRAPHY; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STEREO FUNDUS PHOTOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VISUAL ACUITY;

EID: 84881325465     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113139990048     Document Type: Article

References (26)

1. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011; 129(1): 75-80.
2. Jonasson F, Arnarsson A, Eiriksdottir G, et al. Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study. Ophthalmology 2011; 118(5): 825-830.
3. De Jong PT. Age-related macular degeneration. N Engl J Med 2006; 355(14): 1474-1485.
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26(4): 383-390.
8. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008; 86(5): 482-489.
9. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52(7): 4694-4702.
10. Brantley MA, Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114(12): 2168-2173.
11. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96(2): 208-212.
12. Lin JM, Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 2008; 145(6): 1045-1051.
13. Yu Y, Bhangale TR, Fagerness J, et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet 2011; 20(18): 3699-3709.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
15. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118(4): 663-671.
16. Boekhoorn SS, Isaacs A, Uitterlinden AG, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology 2008; 115(11): 1899-1903.
17. Corbo JC, Lawrence KA, Karlstetter M, et al. CRX ChIP-seq reveals the cis-regulatory architecture of mouse photoreceptors. Genome Res 2010; 20(11): 1512-1525.
18. Chen Y, Bedell M, Zhang K. Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv 2010; 10(5): 271-281.
19. Ni Dhubhghaill SS, Cahill MT, Campbell M, Cassidy L, Humphries MM, Humphries P. The pathophysiology of cigarette smoking and age-related macular degeneration. Adv Exp Med Biol 2010; 664: 437-446.
20. Cano M, Thimmalappula R, Fujihara M, et al. Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration. Vision Res 2010; 50(7): 652-664.
21. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 1998; 147(2): 103-10.
22. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108(4): 697-704.
23. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009; 10: 19-43.
24. Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology 1996; 103(6): 871-877.
25. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 2001; 119(8): 1191-1199.
26. Montezuma SR, Sobrin L, Seddon JM. Review of genetics in age related macular degeneration. Semin Ophthalmol 2007; 22(4): 229-240.